TGTX / Ocrevus Challenges Briumvi: A Closer Look At TG Therapeutics' Position

The company reported Q3 results that were much better than expected. An up-front licensing payment from Neuraxpharm was a big factor in these surprisi more_horizontal

TG Therapeutics Inc (NASDAQ:TGTX) stock is soaring today, after the biopharmaceutical name's third-quarter results smashed analyst expectations. more_horizontal

TG Therapeutics, Inc. stock has declined by 75% since its approval highs, with little hope of recovery. The company's fortunes have been tied to its e more_horizontal

TG Therapeutics (NASDAQ: TGTX) stock price sell-off continued this week as concerns about the rising competition continued. The shares plunged to a lo more_horizontal

TG Therapeutics has transitioned from a developer of oncology drugs to a commercial-stage neurology company with the approval of its multiple sclerosi more_horizontal

Fireside chat scheduled for Tuesday, September 26, 2023, at 12:25 PM ET Fireside chat scheduled for Tuesday, September 26, 2023, at 12:25 PM ET more_horizontal

Following a disappointing outcome for the second quarter, shares of biotechnology firm TG Therapeutics (NASDAQ: TGTX ) suffered a catastrophic loss. S more_horizontal

The launch of Briumvi is off to a solid start, but the stock pulled back recently and fell more after Roche reported positive phase 3 results of subcu more_horizontal